Background/Aims: Fibroblast growth factors (FGFs) and their high-affinity receptors contribute to autocrine and paracrine growth stimulation in several human malignant tumors, including breast cancer. However, the mechanisms underlying the carcinogenic actions of FGF18 remain unclear. Methods: The transcription level of FGF18 under the hypoxic condition was detected with quantitative PCR (qPCR). A wound-healing assay was performed to assess the role of FGF18 in cell migration. A clonogenicity assay was used to determine whether FGF18 silencing affected cell clonogenicity. Western blotting was performed to investigate Akt/GSK3β/β-catenin pathway protein expression. Binding of β-catenin to the target gene promoter was determined by chromatin immunoprecipitation (ChIP) assays. Results: FGF18 promoted the epithelial-mesenchymal transition (EMT) and migration in breast cancer cells through activation of the Akt/GSK3β/β-catenin pathway. FGF18 increased Akt-Ser473 and -Thr308 phosphorylation, as well as that of GSK3β-Ser9. FGF18 also enhanced the transcription of proliferation-related genes (CDK2, CCND2, Ki67), metastasis-related genes (TGF-β, MMP-2, MMP-9), and EMT markers vimentin, TIMP1). β-catenin bound to the target gene promoter on the ChIP assay. Conclusion: FGF18 contributes to the migration and EMT of breast cancer cells following activation of the Akt/GSK3β/β-catenin pathway. FGF18 expression may be a potential prognostic therapeutic marker for breast cancer.
FGF18 Enhances Migration and the Epithelial-Mesenchymal Transition in

Introduction
Breast cancer, first recognized by the Egyptians more than 3500 years ago [1] , is currently the most common form of cancer and the second leading cause of death from cancer among women. An estimated 1 to 1.3 million breast cancer cases are diagnosed annually worldwide. Breast cancers can be divided into molecular subtypes based on the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Moreover, with the development of genetic diagnostic techniques such as cDNA microarrays, a novel classification system for breast cancer has been introduced, with the ER + group divided into at least three subgroups [2] . These cancers can be treated with hormone therapy as an effective and significantly less toxic alternative to chemotherapy. Among the subtypes, triple-negative (ER -, PR -, and HER2 -) breast cancers have a particularly poor prognosis. In addition, the expression of proliferative markers such as Ki-67 is used for further prognostic distinction of molecular subtypes [3] .
Over the past few decades, our understanding of breast cancer and its treatment has undergone a metamorphosis, shifting from generally indiscriminate to a more personalized approach based on gene expression analysis and the development of markers that can aid informed diagnostic and treatment decisions [2, [4] [5] [6] [7] [8] [9] [10] [11] [12] . Recently, a new panel of markers involving the relative expression of FGF18, BCL2, PRC1, MMP-9, and SERF1A was identified and validated for risk prediction in early breast cancer [8] .
FGF18 is a 21.2 kDa glycosylated secretory protein that is highly conserved among humans, mice, and rats. The structure of FGF18 is similar to that of FGF8 and FGF17, which together constitute the FGF8 subfamily [13] . As a mitogenic, chemotactic, and angiogenic factor, FGF18 is essential for the embryonic and postnatal development of multiple tissues, such as bone, cartilage, hair, and vasculature [13] [14] [15] [16] . Overexpression of FGF18 has been frequently identified in synovial sarcoma, hepatocellular carcinoma, and colon and ovarian cancers [17] [18] [19] [20] [21] . FGF18 is also an informative prognostic and therapeutic biomarker for a subset of ovarian cancers [20, 21] .
Despite the apparent importance of FGF18 in the pathogenesis of ovarian and breast cancers, few studies have addressed the mechanistic aspects of FGF18 in tumorigenesis. The purpose of this study was to investigate the role of FGF18 in migration and the epithelialmesenchymal transition (EMT) and to determine why it preferentially reappears in hormonal cancers.
Materials and Methods
Cell culture MCF-7, MDA-MB-453, SK-BR-3 and T47D breast cancer cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA), and cultured in HyClone TM High-Glucose DMEM medium (Thermo, Cat. SH30243.01B) supplemented with 10% fetal bovine serum (Gibco, Cat. 10099-133) and 1% penicillin/streptomycin (Thermo, Cat. 15140122).
TCGA and OncoLnc analyses
The FGF18 mRNA expression and the FGF18 gene copy number of clinical breast cancer tissues were examined with Oncomine web (https://www.oncomine.org/resource/main.html), which the data based on The Cancer Genome Atlas (TCGA). In the Oncomine web, we set the filter as following: Gene: FGF18; Analysis type: Cancer vs. Normal Analysis; Cancer type: Breast cancer. The results were displayed as following: Group by: Cancer and normal type; Fingure type: Box-plot. The detail instructions for use, please refer to the Oncomine Support Community (https://support.oncomine.com/?authToken=1fc8a8a156c3ae215016c1ba 3d804575). The survival rates of the patients with FGF18 expression based on website of OncoLnc (http:// www.oncolnc.org/). In the OncoLnc web, we set the filter as following: Target gene: FGF18; Cancer type: Breast cancer. The detail instructions for use, please refer to the Guide to OncoLnc: A new TCGA data portal (https://www.lncrnablog.com/guide-to-using-oncolnc-a-new-tcga-data-portal/). 
Clonogenicity assay
Forty-eight hours after transfection (described as siRNA), cells were plated at a low density in a DMEM medium containing 10% fetal bovine serum (FBS). After 10 days in culture, the cancer cells formed colonies, which were stained with methyl violet. Colony numbers were quantified by counting colonies that contained more than 25 cells observed under a light microscope. The numbers of clones were determined in at least three dishes per group. The statistical analyses for p values were obtained using SPSS18.0 software (SPSS, Inc., Chicago, IL, USA).
RNA isolation and quantitative reverse-transcriptase PCR (qPCR)
Total RNAs were isolated using the RNeasy Mini Kit (QIAGEN, Cat. 74104). 1 µg total RNAs were reversely transcribed into cDNAs using a Super Script Western blotting assay 2-5 ×10 6 cells were lysed with 1 ml of lysis buffer (50 mM Tris-HCl, pH7.2, 1% NP-40, 150 mM NaCl, 50 mM β-Glycerophosphate disodium salt hydrate, 5 mM DL-Dithiothreitol, 0.1 mM PMSF) plus protease inhibitors (Sigma-Aldrich) for 30 min on ice. After centrifugation at 10000 rpm for 15 min at 4°C, the lysates were boiled with 5 × sample buffer, then separated by SDS-PAGE and transferred to PVDF membrane.
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Immunoblotting was performed as described [22] and visualized by chemiluminescence (Bio-Rad, Series No. ChemiDoc XRS+). Antibodies used for immunoblotting were as follows: FGF18 (Abcam, Cat. Ab86571), Akt (Santa Cruz, Cat. sc-8312), p-Akt Ser473 (Santa Cruz, Cat. sc-7985-R), p-Akt Thr308 (Santa Cruz, Cat. sc-16646-R), p-GSK3β Ser9 (Cell Signaling, Cat. #9323), p-GSK3β Tyr216 (Santa Cruz, Cat. sc-135653), GSK3β (Santa Cruz, Cat. sc-9166), β-catenin (Cell Signaling, Cat. #8480), Actin (Santa Cruz, Cat. sc-1616-R) and anti-rabbit IgG antibodies conjugated to horseradish peroxidase (Abcam, Cat. ab6721).
Chromatin immunoprecipitation(ChIP) and quantitative ChIP (qChIP)
qChIP assay was performed as reported previously [22, 23] . Briefly, 2×10 7 MDA-MB-453 cells were collected by centrifugation at 2000 g for 5 min at room temperature and cross-linked in PBS containing 1% formaldehyde for 10 min on ice. The reaction was stopped by adding glycine to a final concentration of 0.125 M. ChIP assay was performed by incubation of the chromatin with 20 µL rabbit mAb β-catenin antibody (Cell Signaling, Cat. #8480) or normal rabbit IgG (Cell Signaling, Cat. #2729). Enrichment of the ChIP sample over input was evaluated by qPCR with specific primers in the promoter region of target genes. Three technical replicates were performed. 
Statistical Analysis
All data are expressed as mean ± standard deviation at least three independent experiments. Twotailed p-value less than 0.05 was viewed as statistically significant (displayed as *p < 0.05, ** p < 0.01, ***p < 0.001). All analyses were performed using SPSS 19.0 software (Statistical Package for Social Studies, Chicago, IL, USA).
Results
FGF18 expression and its relationship with breast cancer patient survival
To clarify the relationship between FGF18 expression and breast cancer incidence, we examined FGF18 expression and gene copy number via the Oncomine website (https:// www.oncomine.org/resource/main.html) [24] , which is based on The Cancer Genome Atlas database (https://cancergenome.nih.gov/). FGF18 mRNA levels (n=582) and gene copy number (n=229) were significantly increased in breast cancer samples compared with normal breast tissues (Fig. 1A-B) . Furthermore, analysis of FGF18 protein content using the Human Protein Atlas database (http://www.proteinatlas.org/) revealed that FGF18 tended to be highly expressed in breast cancer samples compared with normal tissue (Fig. 1C) .
Next, we analyzed the survival rates of patients with high (n=150) and low (n=150) levels of FGF18 expression based on the OncoLnc website (http://www.oncolnc.org/) [25] . As shown in Fig. 1D , a higher expression of FGF18 was associated with worse breast cancer patient survival. Altogether, the high expression of FGF18 appears to be a biomarker of poor prognosis, which indicates that FGF18 may play a significant role in the development of breast cancer. 
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Upregulation of FGF8 family genes in breast cancer cell lines under hypoxic conditions
Rapidly growing tumors such as breast cancer often suffer from an inadequate blood supply. Hypoxia is one of the inducers of breast cancer development that causes breast cell damage via increased reactive oxygen species (ROS) production [26] . Therefore, we wondered whether a lack of oxygen leads to the upregulation of the FGF8 subfamily in breast carcinoma. When the breast cancer cell lines MCF-7, MDA-MB-453, SK-BR-3, and T47D were cultured with the hypoxia-mimetic drug deferoxamine mesylate for 48 h, the transcript levels of FGF8, FGF17, and FGF18 were increased up to 20-fold within 48 h above the already considerable expression levels in control cultures (Fig. 2) . These results demonstrated that hypoxia could induce the expression of the FGF8 subfamily.
Effects of FGF18 on cell migration in MDA-MB-453 and SK-BR-3 cells
To investigate whether FGF18 expression increases cancer cell motility, a wound-healing assay was performed in MDA-MB-453 and SK-BR-3 cells treated with 10 ng/ml and 20 ng/ml FGF18. FGF18-treated cells were able to migrate more rapidly, with the migration distance dependent on the FGF18 concentration (Fig. 3A-D) . We also observed that MDA-MB-453 cells were more sensitive to FGF18 stimulation than SK-BR-3 cells, and therefore chose the MDA-MB-453 cell line for further analyses.
FGF18 silencing reduces clone formation in MDA-MB-453 cells
To assess the role of FGF18 in the malignant behavior of MDA-MB-453 cells, the expression of FGF18 was knocked down by small interfering RNA (siRNA). As shown in Fig. 3E, FGF18 siRNA significantly decreased both the protein and mRNA expression levels of FGF18 compared with scrambled siRNA. More importantly, knockdown of FGF18 also markedly decreased the clonal formation ability of MDA-MB-453 cells (Fig. 3F) .
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
Song et al.: FGF18 Promotes Migration and EMT in Breast Cancer
Effects of FGF18 on the expression of proliferation-, migration-, and EMT-related genes in MDA-MB-453 cells
To explore FGF18-mediated downstream events, we isolated total RNA from MDA-MB-453 cells treated with 10 ng/ml FGF18 and performed qRT-PCR to assess the expression levels of target genes related to proliferation, migration, and the EMT. Proliferation-related genes, including CDK2, CCND2, and Ki67, were significantly upregulated in MDA-MB-453 cells exposed to 10 ng/ml FGF18 (Fig. 4A) . The expression levels of TGF-β, MMP-2, and MMP-9, which are involved in tumor migration activities, were notably increased after FGF18 treatment (Fig. 4B) . The EMT markers, including Snail-1, Snail-2, N-cadherin, vimentin, and TIMP-1, were also significantly upregulated in response to FGF18 stimulation. In contrast, the expression of E-cadherin was significantly decreased in MDA-MB-453 cells after treatment with FGF18 (Fig. 4C ). E-cadherin is one of the epithelial molecular markers that is always downregulated during EMT progression [27, 28] .
Effects of FGF18 on Akt/GSK3β/β-catenin signaling in MDA-MB-453 cells
To further explore whether FGF18 promotes carcinogenesis in breast cancer by activating the Akt pathway, we performed western blotting. As shown in Fig. 5 , the expression levels of phospho-Akt-Ser473 (p-Akt-Ser473) and phospho-Akt Thr308 (p-AktThr308) were increased after FGF18 treatment in a dose-dependent manner. Both phosphorylation sites are indicative of Akt activation. We next tested GSK3β expression, which is a main downstream target of Akt activation. FGF18 treatment was followed by phosphorylation of Ser9 (p-GSK3β-Ser9), but not Tyr216 (p-GSK3β-Tyr216). The total β-catenin level was also found to be upregulated in the FGF18-treated cells, suggesting a downstream link to the changes in EMT-related gene expression. Overall, our findings indicate that FGF18 regulates the genes related to breast carcinogenesis via Akt/GSK3β-mediated β-catenin signaling (Fig. 5) .
To further ascertain how β-catenin regulates proliferation-, migration-, and EMT-related genes, we performed a chromatin immunoprecipitation assay (ChIP) and quantitative ChIP with β-catenin antibody in MDA-MB-453 cells. As shown in Fig. 6 , ChIP analysis revealed that β-catenin bound to the promoters of CDK2, CCND2, and Ki67, as well as several migration (TGF-β, MMP-2, MMP-9)-and EMT (Snail-1, Snail-2, N-cadherin, vimentin, and TIMP1)-related genes. 
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Discussion
FGF18 is overexpressed in several types of tumors and has also been considered a potential prognostic and therapeutic biomarker [17] [18] [19] [20] [21] . FGF18 promotes the development and progression of hepatocellular malignancies, colorectal cancers, and synovial sarcomas by stimulating tumor cell growth or survival [17] [18] [19] . As a secreted protein, FGF18 controls migration, invasion, and tumorigenicity in ovarian cancer cells and, by increasing the production of oncogenic cytokines and chemokines, affecting the tumor microenvironment [20, 21] . Because ovarian cancer is strongly associated with the basal-like subtype, a subtype regrouping of triple-negative breast cancer, we believe that FGF18 may also promote breast carcinogenesis [2, 29] .
All mammalian FGF ligands activate one or more of four distinct cell-surface receptor tyrosine kinases (FGFR1-FGFR4) . FGFR4, also called FGFR3c, is one of the receptors for FGF18 [21] and is implicated in the function of FGF18 as a mesenchymal growth factor [30, 31] . In colorectal cancer, FGFR4 acts as an oncogene and FGF18 is upregulated as a β-catenin target gene [18, 32] . The therapeutic potential of FGFR inhibitors is presently under investigation in clinical trials in breast cancer patients [33] .
β-catenin is capable of enhancing FGF18 transcription because the promoter of human FGF18 harbors T cell factor/lymphoid enhancer-binding factor binding sites [34] . In our ChIP studies, we also found that β-catenin binds to the promoters of the proliferation, migration, and EMT genes being studied. The expression of FGF18, in combination with other markers, also predicts the risk of breast cancer [35] . However, although the importance of FGF18 is well established, the mechanisms underlying the involvement of FGF18 in breast cancer development and progression remain largely elusive. Here, we addressed this question using breast cancer cell lines in vitro.
In this study, we found pronounced overexpression of the FGF8 subfamily in human breast cancer cell lines under hypoxic conditions. We further found that FGF18 could increase the motility of cells in a time-and dose-dependent manner, as determined by tracking the distance traveled in a wound-healing assay. In agreement with the wound-healing results, genes involved in migration, including TGF-β, MMP-2, and MMP-9, were overexpressed in MDA-MB-453 cells after FGF18 treatment.
The EMT is a process that involves transition to the mesenchymal state and causes cells to gain migratory and invasive properties, key events in cancer metastasis [36] [37] [38] [39] . Our results showed that the expression levels of cancer metastasis-related genes, such as Snail-1, Snail-2, N-cadherin, vimentin, and TIMP-1, were markedly increased after FGF18 treatment. In contrast, E-cadherin, an epithelial marker, was downregulated. These results suggest that FGF18 may induce the EMT and contribute to malignization through inhibition of E-cadherin expression and stimulation of EMT-related genes. In addition, we also concluded that the application of exogenous FGF18 could increase the expression of proliferation-related genes, such as CDK2, CCND2, and Ki67.
Akt/GSK3β signal pathway plays an important role in the development of tumors [40] . Our data indicate that FGF18 may promote breast carcinogenesis through the Akt/GSK3β/β-catenin pathway. FGF18 induced the phosphorylation of Akt at Ser473 and Thr308 sites and inactivated GSK3β by elevating Ser9 modification, but not Tyr216. Based on the present data and the evidence available in the literature, we have outlined a hypothetical model to explain our findings (Fig. 7) . In this model, FGF18 upregulates Akt phosphorylation at Ser473 and Thr308 sites and then triggers GSK3β phosphorylation at Ser9 (p-GSK3β-Ser9, an inactive form of GSK3β), but not Tyr216 (p-GSK3β-Tyr216, an active form of GSK3β that mainly mediates the degradation of GSK3β). As a result, the inactive GSK3β leads to β-catenin accumulation in the cytoplasm and its translocation to the nucleus, where β-catenin triggers the expression of multiple genes, such as CDK2, CCND2, Ki67, TGF-β, MMP-2, MMP-9, Snail-1, Snail-2, and N-cadherin, responsible for cell survival, migration, and the EMT [41] .
The FGF18-mediated signaling in the breast cancer cell lines used in our study further confirms the utility of FGF18 as a reliable biomarker for cancer, as previously reported in other systems [42] [43] [44] . However, the present study was limited to HER + breast cancer cell lines (MDA-MB-453, SKBR3) and not triple-negative breast cancercell lines. Thus, our results have to be confirmed in triple-negative breast cancer cells and in vivo.
Conclusion
In summary, our data demonstrate that FGF18 exerts oncogenic effects in HER + breast cancer cells by promoting cell proliferation and migration in vitro. This makes FGF18 a promising candidate target for basic study or clinical research in non-triple-negative breast cancers.
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